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The role of high-dose therapy followed by
autologous stem cell transplantation
(ASCT) in the treatment of multiple my-
eloma (MM) continues to evolve in the
novel agent era. The choice of induction
therapy has moved from conventional
chemotherapy to newer regimens incor-
porating the immunomodulatory deriva-
tives thalidomide or lenalidomide and the
proteasome inhibitor bortezomib. These
drugs combine well with traditional thera-
pies and with one another to form various
doublet, triplet, and quadruplet regimens.
Up-front use of these induction treat-
ments, in particular 3-drug combinations,
has affected unprecedented rates of com-
plete response that rival those previously
seen with conventional chemotherapy and
subsequent ASCT. Autotransplantation
applied after novel-agent-based induc-
tion regimens provides further improve-
ment in the depth of response, a gain that
translates into extended progression-free
survival and, potentially, overall survival.
High activity shown by immunomodula-
tory derivatives and bortezomib before
ASCT has recently led to their use as
consolidation and maintenance therapies
after autotransplantation. Novel agents
and ASCT are complementary treatment
strategies for MM. This article reviews the
current literature and provides important
perspectives and guidance on the major
issues surrounding the optimal current
management of younger, transplanta-
tion-eligible MM patients. (Blood. 2011;
117(23):6063-6073)
Introduction
Multiple myeloma (MM) is a disease of the elderly. Overall, only
35% of the patients are younger than 65 years at the time of
diagnosis, whereas the remaining two-thirds are older.1 Age is an
independent prognostic factor in MM2 and, importantly, provides a
major criterion by which patients can be considered eligible to
tolerate high-dose therapy (HDT) with autologous hematopoietic
stem cell transplantation (ASCT). Over the last decade, the survival
of patients with newly diagnosed MM, particularly those younger
than 60 years, has significantly improved.3 The widespread use of
ASCT and the introduction into clinical practice of the novel agents
bortezomib and the immunomodulatory derivatives (IMiDs) thalido-
mide and lenalidomide have significantly contributed to major
advances in MM therapy and prognosis.4,5
Thalidomide or bortezomib combined with melphalan and predni-
sone represent new standards of care for elderly, transplantation-
ineligible MM patients.6-8 In this setting, lenalidomide in combination
with low-dose dexamethasone is an alternative treatment option.9 In
younger patients, the novel agents have been incorporated into the
therapeutic algorithm along with ASCT to improve clinical out-
comes.10-12 In particular, these drugs have been used as part of induction
therapy before ASCT and as consolidation/maintenance after autotrans-
plantation. This manuscript from the International Myeloma Working
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Group (IMWG) presents an overview of the most recent studies of novel
agents combined with ASCT and focuses on the main areas of current
debate, including the choice of induction regimen, the role of post-
ASCT consolidation and maintenance therapies, the impact on
prognosis of ASCT incorporating the new drugs, and the manage-
ment and prevention of major toxicities related to the use of novel
therapies.
What is younger?
There is no formal definition of a younger patient with MM,
although this term is commonly used to identify a person for whom
ASCT is planned as part of the treatment program. As many phase
3 studies of ASCT have enrolled patients with an upper age limit
not exceeding 65 years,13-19 younger MM patients are often
operatively defined as being 65 years of age and younger. However,
this arbitrary cut-off does not exclude patients who are older than
65 years from ASCT. In particular, in selected patients up to the age
of 70 to 75 years who are medically fit, ASCT is a treatment option
that can be performed safely at most specialized transplantation or
myeloma centers.20 Unlike in younger patients, benefits from
ASCT have not been consistently demonstrated in the elderly.
When to start myeloma-specific therapy
When symptomatic, or active, MM is diagnosed based on the
presence of organ damage related to the underlying malignant
clone (eg, hypercalcemia, renal insufficiency, anemia, and bone
disease),21 therapy is required immediately. By contrast, patients
with asymptomatic or smoldering MM are closely observed
without specific therapy until the disease progresses to a symptom-
atic phase. Clinical trials are currently underway to investigate
whether novel agents can delay the risk of progression from
smoldering to active MM and improve overall survival (OS).22 At
present, the IMWG does not recommend treatment for smoldering
MM but considers patients at high risk of progression to symptom-
atic disease as candidates for investigative clinical trials.
Single ASCT
Over the last decade, ASCT has been considered the standard of
care for younger patients with newly diagnosed MM23-25 based on
the increased rate of complete response (CR) and prolonged OS
compared with conventional chemotherapy in several randomized
studies.13,14 However, not all the studies published so far have
uniformly demonstrated the superiority of ASCT over chemo-
therapy at standard doses.16-18 A number of factors may account for
these discrepancies, including treatment crossover for patients
randomized to conventional treatment, possible bias in patient
selection criteria, and differences between studies with respect to
the intensity and duration of conventional therapy. A systematic
review and meta-analysis of randomized studies has shown a
significant benefit with single ASCT in terms of prolonged
progression-free survival (PFS), but not of OS.26 However, these
results should be cautiously interpreted because of methodologic
limitations of the analysis and significant heterogeneity across
different studies. An alternative to autotransplantation up-front is to
delay HDT with ASCT at the time of relapse. Although in a pilot
study the length of OS for patients receiving early or late ASCT
after conventional induction chemotherapy was equivalent, early
autotransplantation was associated with a longer event-free sur-
vival (EFS) and better quality of life.27 In the novel agent era, the
issue of early versus late ASCT needs to be reevaluated in the
context of large randomized clinical trials. Two of these studies are
currently ongoing, one of them headed by the European Myeloma
Network and the other performed by a consortium of centers in
France and the United States. While final results of these studies are
awaited, the IMWG recommends that ASCT should be offered at
some point in the course of the treatment program for a patient
eligible to receive HDT. Although favorable results with ASCT
up-front are backed by phase 3 studies, increasing numbers of
patients and physicians, particularly in United States, are currently
opting to collect stem cells early and deferring transplantation at
the time of relapse.
Double ASCT
Five randomized trials directly addressed the question of single
versus double, or tandem, ASCT as up-front therapy for
MM.15,19,28-30 Results were conflicting because of differences
between studies with respect to their structural and methodologic
characteristics. In particular, although extended EFS with double
ASCT was observed in most of the trials, an OS benefit was
demonstrated in only 2 of them. A meta-analysis of data pooled
from controlled clinical trials (one of which has been recently
retracted) failed to show superior OS with double ASCT which, by
the opposite, was associated with improved response rates and
EFS.31 A number of concerns related to the methodology of the
analysis and errors involving data extractions have been raised,
suggesting that these caveats might have negatively influenced the
conclusion.32,33 More recently, a report of long-term outcomes of
several trials of autotransplantation(s) confirmed superior results
offered by double ASCT compared with a single transplantation.34
In 2 studies of double ASCT, post-hoc subgroup analyses
showed that the second autotransplantation improved clinical
outcomes in those patients who failed high-quality responses after
the first ASCT.15,19 However, a major limitation of these studies
was their lack of power to demonstrate the equivalence of 1 versus
2 transplants for patients with high-quality responses after the first
course of HDT. With the recent availability of highly effective
novel agents, the role of single versus double ASCT is being
explored in the context of prospective, randomized clinical trials,
such as that currently headed by the Bone Marrow Transplant
Clinical Trials Network. In the meantime, the IMWG suggests
considering timely second ASCT in those patients who fail to
achieve a very good partial response (VGPR) or better after the
first ASCT.
Prognostic relevance of CR
Attainment of CR after both induction therapy and ASCT is one of
the strongest predictors of long-term outcomes35,36 and represents a
major endpoint of current treatment strategies incorporating auto-
transplantation up-front. To more carefully identify high-quality
responses occurring beyond the CR level, the IMWG has recently
introduced the category of stringent CR, as defined by negative
immunofixation, normal free-light chain ratio, and absence of
clonal bone marrow plasma cells by immunohistochemistry.37 It is
probable that incorporation of novel agents into ASCT results in
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increased rates of immunophenotypic and/or molecular remis-
sions38 compared with that reported in the recent past.
Other studies have also emphasized the adverse prognostic
importance of residual focal lesions detected by magnetic reso-
nance imaging.39 In contrast, sustained CR is predictive of favor-
able long-term outcomes.40 Therefore, not only attainment of CR
per se, but maintenance of a durable CR, appears to be a major
prognostic variable in MM. Interestingly, achievement of CR does
not seem to be of critical prognostic relevance for several
subgroups of patients, including those with low-risk disease or in
whom active MM reverts to an indolent phase similar to that of
monoclonal gammopathy of undetermined significance.41
Review of evidence supporting newer
induction treatments in preparation for ASCT
Patients who are eligible for early ASCT typically receive a limited
number of cycles of induction therapy to reduce tumor cell mass
and bone marrow plasma cell infiltration before collection of
peripheral blood stem cells. Compared with conventional treat-
ments used in the past, a number of novel agents are now available
that affect increased rates of CR. Currently, these novel agents are
incorporated into induction regimens to enhance the depth of
response before ASCT and further improve post-ASCT outcomes.
Thalidomide and dexamethasone
The activity of thalidomide, especially when combined with
dexamethasone (TD), in the relapsed/refractory setting has pro-
vided the rationale for the design of phase 2 and 3 trials
investigating the role of this regimen in patients with newly
diagnosed disease.42-44 In 2005, a retrospective case-matched study
provided the first demonstration of superior rate and depth of
response affected by TD compared with VAD as induction therapy
in preparation for ASCT,42 a finding confirmed by a subsequent
phase 3 study43 (Table 1). Based on the results of a randomized
study showing a higher response rate with TD compared with
high-dose dexamethasone44 (Table 1), the United States Food and
Drug Administration granted accelerated approval for TD in
patients with newly diagnosed MM. As a result, over the past years,
TD has emerged as one of the most commonly used induction
regimens in the United States and European countries (European
Union).
In 2 additional studies in which TD was incorporated into
double ASCT and given from the outset through the second
ASCT45 or until relapse/progression,46 superior rates of CR or at
least VGPR, EFS, and OS were seen with TD plus double ASCT
compared with tandem transplantation not incorporating thalido-
mide (Table 1). However, the rate of adverse events, in particular
peripheral neuropathy and venous thromboembolism, was consis-
tently high with thalidomide maintenance therapy and led to drug
discontinuation in 30% and 60% of patients after 2 and 4 years,
respectively.46
Thalidomide-dexamethasone and a
cytotoxic drug
Two phase 3 trials explored the activity of induction regimens
combining TD with doxorubicin or cyclophosphamide in transplan-
tation candidates. In one study, TD and doxorubicin provided a
significantly higher rate of VGPR or better compared with VAD
(37% vs 18%), a gain that was maintained after the first ASCT
(54% vs 44%, respectively).47 Median EFS for patients randomly
assigned to TD and doxorubicin followed by post-ASCT thalido-
mide maintenance was 34 months versus 22 months for those
assigned to VAD and subsequent maintenance with interferon.
In another study, superior rates of CR both before and after
ASCT were seen with TD and cyclophosphamide compared with
cyclophosphamide added to VAD (pre-ASCT, 19% vs 9%; and
post-ASCT, 51% vs 40%, respectively).48
Table 1. Phase 2 and 3 studies of thalidomide-dexamethasone and triplet thalidomide-based combinations in preparation for ASCT
Regimen N
After induction After ASCT
PFS OS ReferenceCR  PR, % CR/ > VGPR, % CR  PR, % CR/ > VGPR, %
TD vs 100 76 10/19 NR NR NR NR 42
VAD (retrospective case-matched study) 100 52 8/14 NR NR NR NR
TD vs 103 63 4/NR NR NR NR NR 44
VAD 104 41 0/NR NR NR NR NR
TD vs 100 66 NR/35 68 NR/44 NR NR 43
Descamethasone 104 52 NR/13 62 NR/42 NR NR
TAD vs 268 71 3/37 84 14/54 median, 34 mo median, 73 mo 47
VAD 268 57 2/18 76 12/44 median, 22 mo median, 60 mo
P  .001 P  .77
CTD vs NR 87 19/NR NR 51/NR NR NR 48
CVAD NR 75 9/NR NR 40/NR NR NR
TT2  THAL vs 323 NR NR NR 62/NR 5-yr, 56% 5-yr, 65% 46
TT2 without THAL 345 NR NR NR 43/NR 5-yr, 44% 5-yr, 65%
P  .01 P  .90
Double ASCT  THAL vs 135 NR NR/30 NR NR/68 4-yr, 51% 5-yr, 69% 45
Double ASCT without THAL (retrospective
case-matched study)
135 NR NR/15 NR NR/49 4-yr, 31% 5-yr, 53%
P  .001 P  .07
Studies incorporating thalidomide-dexamethasone throughout double ASCT are also included.
CTD indicates cyclophosphamide, thalidomide, dexamethasone; CVAD, cyclophosphamide added to VAD (vincristine, doxorubicin, dexamethasone); NR, not reported;
TAD, thalidomide, doxorubicin, dexamethasone; TD, thalidomide, dexamethasone; THAL, thalidomide; and TT2, Total Therapy 2.
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Bortezomib and dexamethasone
The role of up-front standard-dose bortezomib (1.3 mg/m2) given
twice weekly either as a single agent or with added dexamethasone
in patients with suboptimal response to the first cycles of therapy
was initially explored in patients who were either eligible or
ineligible for ASCT (Table 2).49,50 In 2 additional phase 2 studies,
bortezomib and high-dose dexamethasone (VD) were given either
in combination51 or on an alternating basis52 before ASCT. The rate
of at least VGPR was 31% with VD and 22.5% with the alternating
schedule; the corresponding value after ASCT was 55% in each of
the 2 studies. In a phase 3 study, VD was prospectively compared
with VAD as induction therapy in preparation for single or double
ASCT; in both arms, lenalidomide was given as post-ASCT
consolidation and maintenance therapy.53 After 4 21-day cycles, the
rates of at least VGPR, including CR and near CR (nCR), affected
by VD were significantly higher than with VAD ( VGPR, 38% vs
15%; CR-nCR, 15% vs 6%, respectively), a gain maintained after
both the first and second ASCT ( VGPR, 68% vs 47%; CR-nCR,
39.5% vs 22.5%, respectively). A borderline, albeit not statistically
significant, PFS benefit was seen in the VD arm compared with the
VAD arm (median, 36 vs 30 months, respectively).
Bortezomib-dexamethasone and a
cytotoxic drug
Cytotoxic drugs added to VD as part of a 3-drug regimen in
preparation for ASCT have included doxorubicin or cyclophosph-
amide (Table 2). A combination of bortezomib, doxorubicin, and
dexamethasone, referred to as PAD, was investigated in 2 small
cohorts of patients who received either standard-dose or reduced-
dose bortezomib (1.0 mg/m2) on a twice-weekly basis (Table 2).54
In a phase 3 study, the PAD regimen was compared with VAD as
induction therapy before 1 or 2 autotransplantations.55 Superior
CR-nCR rates were seen with PAD compared with VAD after both
induction (11% vs 5%, respectively) and autotransplantation(s)
(30% vs 15%). PAD induction followed by ASCT and subsequent
bortezomib maintenance was associated with significantly longer
PFS and OS compared with VAD induction and post-ASCT
thalidomide maintenance therapy (Table 2). Two additional phase
2 studies confirmed the activity of a PAD-like induction regimen
incorporating pegylated liposomal doxorubicin (Table 2).56,57
In addition, cyclophosphamide has also demonstrated substan-
tial activity when combined with VD (CyBorD or VCD) in
preparation for ASCT.58,59 In 2 phase 2 studies, the rate of at least
VGPR was between 37% and 61%, a range that reflected heteroge-
neities between studies with respect to the number of planned
treatment cycles and the delivered cyclophosphamide dose.
Bortezomib, dexamethasone, and
thalidomide
Preclinical data suggesting that IMiDs increase bortezomib activ-
ity, provided the rationale for combining thalidomide with VD
(VTD). Promising rates of high-quality responses reported with
VTD in small cohorts of relapsed/refractory and newly diagnosed
MM patients60 led to the design of a phase 3 study of VTD versus
TD as induction therapy before, and consolidation therapy after,
double ASCT.61 After three 21-day induction cycles, VTD was
superior to TD with respect to all response categories, including
CR, CR-nCR (31% vs 11%), and at least VGPR (62% vs 28%).
Increased frequencies of high-quality responses in the VTD arm
compared with the TD arm were also seen after double autotrans-
plantation and subsequent consolidation therapy (CR-nCR, 62% vs
45%;  VGPR, 85% vs 68%, respectively). The estimated 3-year
PFS for the VTD group of patients was significantly longer than for
those assigned to TD plus double ASCT (68% vs 56%, respec-
tively). In two additional phase 3 studies comparing VTD with
either TD62 or VD63 as induction therapy in preparation for a single
ASCT, superior rates of high-quality responses, both before and
after ASCT, and extended PFS62 were seen with the triplet regimen
(Table 3). Remarkable activity of VTD was further confirmed by
several phase 2 studies,64,65 including a prospective comparison of
VTD with the same regimen combined with cyclophosphamide66
(Table 2).
In Total Therapy 3, VTD combined with cisplatin, doxorubicin,
cyclophosphamide, and etoposide was given as induction therapy
Table 2. Phase 2 studies of bortezomib-based regimens in preparation for ASCT
Regimen N
After induction After transplantation
PFS, median OS, 30 mo Reference
CR  PR,
% CR/ > VGPR, %
CR  PR,
% CR / > VGPR, %
V (single agent) 64 41 NR (9)*/17 NR NR 17 mo 30 mo, 79% 49
V  D 32 87.5 6 (25)*/NR NR NR NR NR 50
VD 48 66 NR (21)*/31 90 NR (33)*/55 NR NR 51
V alternated with D 40 65 12.5/22.5 88 33/55 NR NR 52
PAD-1 21 95 24 (5)*/62 95 43 (14)*/81 median, 29 mo 2-yr, 95% 54
PAD-2 20 89 11 (5)*/42 90 37 (5)*/53 median, 24 mo 2-yr, 73% 54
VDD 50 78 NR (27)*/NR 93 27/NR NR NR 56
VDD 40 85 NR (37.5)*/57.5 87 NR (57)*/77 2-yr, 80% 2-yr, 92% 57
CyBorD 33 88 3 (39)*/61 NR NR (70)*/74 NR NR 58
VCD 391 85.4 NR (15)*/37 NR NR NR NR 59
VTD vs VTDC 49 vs 48 100 vs 96 (29)/69 vs (31)/69 100 vs 100 (50)/87 vs (44)/85 NR 1-yr, 94.1% vs 94.2% 66
TT3  VTD-PACE vs TT2  THAL
(retrospective comparison)
303 vs 323 NR vs NR NR vs NR NR vs NR 2-yr, 54/NR vs 51/NR 2-yr, 84% vs 77%
(P  .008)
2-yr, 87% vs 83%
(P  .12)
67
CyBorD indicates cyclophosphamide, bortezomib, dexamethasone; D, dexamethasone; NR, not reported; PACE, cisplatin, doxorubicin, cyclophosphamide, etoposide;
PAD, bortezomib, doxorubicin, dexamethasone; PAD-2, reduced-dose bortezomib; THAL, thalidomide; TT3, Total Therapy 3; V, bortezomib; VCD, bortezomib,
cyclophosphamide, dexamethasone; VDD, bortezomib, pegylated liposomal doxorubicin, dexamethasone; and VTD, bortezomib, thalidomide, dexamethasone.
*At least near CR.
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before, and consolidation after, double ASCT, whereas VTD
maintenance therapy was continued for 1 year after ASCT.67
Compared with Total Therapy 2 incorporating TD into double
ASCT, Total Therapy 3 significantly improved 2-year EFS (77% vs
84%) and duration of CR.
Lenalidomide, dexamethasone, and other
agents
Lenalidomide plus high-dose dexamethasone (480 mg total in a
28-day cycle; RD) was prospectively compared with lenalidomide
and low-dose dexamethasone (160 mg total per cycle; Rd) as
frontline therapy for MM.9 Patient enrollment into the study was
not restricted by age or eligibility for ASCT. Despite the overall
response rate, including VGPR or better within 4 cycles of therapy
was significantly higher with RD compared with Rd (42% vs 24%,
respectively), a substantially higher toxicity and early mortality
was seen with RD, particularly in patients older than 65 years. On
landmark analysis, the 3-year OS of patients who received ASCT
after RD or Rd was 92%; the corresponding value for patients who
continued on primary therapy and did not receive ASCT was 79%.
Lenalidomide, dexamethasone, and
other agents
Lenalidomide and dexamethasone were combined with bortezomib
to form a triplet regimen (RVD), which has been investigated in
limited series of patients with newly diagnosed MM.68-70 In a phase
1/2 study, a total of 66 patients who were either transplantation-
eligible or ineligible for ASCT received a maximum of 8 RVD
cycles; in responders, RVD maintenance was allowed.69 After
4 cycles, the rate of at least nCR and VGPR was 6% and 11%,
respectively. However, in approximately two-thirds of patients, the
quality of response improved from cycle 4 through cycle 8, and a
further improvement was also seen in the maintenance phase.
In addition to RVD, alternative lenalidomide-containing
regimens have included a combination of lenalidomide-
cyclophosphamide-dexamethasone and a quadruplet regimen in
which cyclophosphamide was added to RVD71 (Table 4). A
prospective comparison of RVD with VCD and cyclophosphamide
combined with RVD given for up to 8 cycles has been recently
reported; the rate of CR-nCR after 4 cycles was in the 7%, 3%, and
Table 3. Phase 3 trials of bortezomib-based regimens in preparation for ASCT
Regimen N
After induction After ASCT
PFS OS ReferenceCR  PR, % CR/ > VGPR, % CR  PR, % CR/ > VGPR, %
VD vs 223 78.5 6 (15)*/38 80 16 (35)*/54 median, 36 mo 3-yr, 81% 53
VAD 218 63 1 (6)*/15 77 9 (18)*/37 median, 30 mo 3-yr, 77%
(P  .06) (P  .5)
VTD vs 236 93 19 (31)*/62 93 42 (55)*/82 3-yr, 68% 3-yr, 86% 61
TD 238 79 5 (11)*/28 84 30 (41)*/64 3-yr, 56% 3-yr, 84%
(P  .005) (P  .3)
VBMCP/VBAD  V vs 129 75 21/36 73 38/51 38 mo NR 62
VTD vs 130 85 35/60 77 46/65 27 mo NR
TD 127 62 14/29 58 24/40 Not reached NR
(P  .006)
PAD vs 371 78 NR (11)*/42 88 NR (30)*/61 3-yr, 36% 3-yr, 78% 55
VAD 373 55 NR (5)*/15 77 NR (15)*/36 3-yr, 27% 3-yr, 70%
(P  .01) (P  .02)
VD vs 99 81 12 (22)*/35 84 33 (54)*/59 NR NR 63
vTD 100 90 13 (32)*/51 90 30 (61)*/73 NR NR
PAD indicates bortezomib, doxorubicin, dexamethasone; V, bortezomib; TD, thalidomide-dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; VBAD,
vincristine, carmustine, doxorubicin, dexamethasone; VBMCP, vincristine, carmustine, melphalan, cyclophosphamide, prednisone; VD, bortezomib, dexamethasone; VTD,
bortezomib (1.3 mg/m2), thalidomide, dexamethasone; vTD, bortezomib (1.0 mg/m2), thalidomide, dexamethasone; and NR, not reported.
*At least near CR.
Table 4. Phase 2 and 3 trials of doublet and triplet lenalidomide-based induction treatments for transplant-eligible and transplant-ineligible
patients
Regimen N
After induction After ASCT
PFS OS Reference
CR  PR
(best response), %
CR/ > VGPR
(best response), % CR  PR, % CR  nCR, %
RD vs 223 81 5/50 NR NR median, 19 mo median, not reached 9
Rd 222 70 4/40 NR NR median, 25 mo median, not reached
(P  .02) (P  .4)
RVD 66 100 29 (39)*/67 NR NR 18 mo, 75% 18 mo, 97% 69
RVD vs 42 83 24 (40)*/50 NR NR NR NR 72
VCD vs 32 75 22 (31)*/41
RVCD 42 86 24 (33)*/57 NR NR NR NR 73
RVDD 57 4 cycles, 96 4 cycles, NR (30)*/58 NR NR NR NR
CRD indicates cyclophosphamide, lenalidomide, dexamethasone; NR, not reported; RD, lenalidomide, high-dose dexamethasone; Rd, lenalidomide, low-dose
dexamethasone; RVD, lenalidomide, bortezomib, dexamethasone; RVCD, lenalidomide, bortezomib, cyclophosphamide, dexamethasone; RVDD, lenalidomide, bortezomib,
pegylated liposomal doxorubicin, dexamethasone; and VCD, bortezomib, cyclophosphamide, dexamethasone.
*At least near CR.
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10% range, respectively.72 An additional quadruplet regimen
incorporating lenalidomide, bortezomib, dexamethasone, and pegy-
lated liposomal doxorubicin was explored.73 After a median of
4 cycles, the rates of CR-nCR and VGPR or better were 30% and
58%, respectively.
Special patient populations
Cytogenetic abnormalities
The prognostic value of major cytogenetic abnormalities and the
impact of novel agents on clinical outcomes of patients carrying
different cytogenetic changes have been recently reviewed by the
IMWG.74 Detection at diagnosis of translocation t(4;14) and
t(14;16) or deletion of chromosome 17, del(17p), by fluorescence
in situ hybridization, as well as deletion/monosomy of del(13q) or
hypodiploidy by metaphase cytogenetics define approximately
one-fourth of patients75 who in the past years did not benefit from
ASCT and had shortened remission duration and OS.76,77
Recent reports have suggested that incorporation of novel
agents into ASCT may overcome, at least in part, the poor
prognosis imparted by high-risk cytogenetic profiles. In two phase
3 studies of VD78 and PAD55 induction therapy followed by
lenalidomide and bortezomib maintenance therapy, respectively,
t(4;14)-positive patients had better outcomes than the control
groups who carried the same abnormality but received VAD
induction followed by maintenance therapy with either lenalido-
mide78 or thalidomide.55 However, in both of these studies, t(4;14)
partly retained its adverse influence on PFS and OS, even among
patients treated with bortezomib-based induction regimens and
subsequent maintenance with novel agents.55,78 In contrast, in a
phase 3 study of VTD induction and consolidation therapy plus
double ASCT, PFS curves were almost identical regardless of the
presence or absence of t(4;14).61 In an additional study, incorpora-
tion of VTD into double ASCT as part of both induction and
consolidation therapy and as post-ASCT maintenance therapy
resulted in improved CR duration, PFS, and OS for the gene
expression profile-defined high-risk subgroup of patients carrying
the MMSET/FGFR3 hybrid transcript.67 The role of bortezomib-
based regimens and ASCT for the treatment of del(17p)-positive
patients needs to be carefully evaluated in larger sample sizes than those
explored so far.78 In particular, areas of major interest include the
ability of less or more intense treatments (eg, doublet vs triplet or
quadruplet combinations) given for different time periods (eg,
short-term vs long-term) to impact on the poor prognosis related to
this high-risk cytogenetic profile.
In most studies incorporating thalidomide as part of induction
therapy79 or as post-ASCT maintenance,80,81 the outcome of
patients with del(13q), t(4;14), and/or del(17p) was inferior to that
of patients who lacked these abnormalities. Conflicting results
concerning the ability of lenalidomide to overcome the poor
prognosis associated with del(13q) and t(4;14) were found in
2 retrospective studies of patients with relapsed/refractory MM.82,83
The adverse prognostic impact of del(17p) was emphasized in one
of these studies.83 In a recent report on newly diagnosed MM
patients who were either transplantation-eligible or ineligible for
ASCT and received lenalidomide-dexamethasone up-front, both
response duration and PFS, but not OS, were significantly worse
when high-risk genetic abnormalities were present at baseline.84
Renal failure
In patients with MM and renal failure, rapid reduction of myeloma
cell mass and recovery of normal renal function are critical goals of
both myeloma-specific therapy and supportive care measures.85
Neither thalidomide86 nor bortezomib87 is excreted through the
kidneys, and dose adjustments are not required for patients with
renal impairment. In contrast, it is mandatory to modify the dose
and schedule of lenalidomide according to renal clearance.85 In
general, bortezomib-based regimens are the preferred treatment
option in this setting, as recently recommended by the IMWG.85
Major toxicities with IMiD- or
bortezomib-based induction therapies
Thalidomide and lenalidomide
For patients who receive thalidomide up-front, either as a single
agent or in combination therapy, the most common toxicities
include constipation, somnolence, and peripheral neuropathy (PN).88
Thalidomide-induced PN is more frequently sensory or sensori-
motor, is dose-dependent (more prevalent with doses higher than
200 mg/day) and duration-dependent (more likely to occur after
6-12 months).89,90 Reduction of the dose or discontinuation of
thalidomide according to the severity of PN are measures com-
monly used in clinical practice. Unlike thalidomide, lenalidomide
induces myelosuppression, mainly neutropenia and thrombocytope-
nia, which can be managed via dose reductions and/or hematopoi-
etic growth factor support.91 PN is uncommonly seen with lenalido-
mide. Another major challenge to be considered in patients who
receive thalidomide or lenalidomide up-front is the increased risk
of thromboembolic complications.92,93 Adequate guidelines on the
most appropriate thromboprophylactic treatments have been pro-
vided by the IMWG.92 Finally, hypothyroidism is an additional
important adverse event associated with long-term therapy incorpo-
rating thalidomide or lenalidomide. Long-term use of lenalidomide
is also associated with severe diarrhea and cramps in a subset
of patients.
The effect of newer induction regimens, in particular those
incorporating lenalidomide, on peripheral blood stem cell mobiliza-
tion and the optimal strategies to obtain adequate stem cell harvests
have recently been reviewed by the IMWG.94
Bortezomib
One of the most important nonhematologic toxicities of bortezomib
is PN, which may lead to impaired quality of life. Bortezomib-
induced PN is predominantly sensory, although in  10% of cases
motor neuropathy has been reported.95 Unlike neurologic toxicity
associated with thalidomide, neuropathic pain, mainly located in
the fingertips and toes, is a major problem with bortezomib. Major
risk factors of bortezomib-induced PN include the cumulative dose
of the drug and treatment schedule. Attempts to decrease the rate
and severity of neurologic toxicity in transplantation candidates
have included either dose reduction of bortezomib given on a
twice-weekly basis63 or once-weekly administration of the drug at a
higher dose to maintain activity.96 In elderly, transplantation-
ineligible patients for whom treatment plan was composed of
long-term exposure to melphalan and prednisone combined with
bortezomib (given twice weekly for 4 cycles, followed by once-
weekly administration for the next 5 cycles), the overall risk of PN
was 47%, including 13% grade 3 or 4.8 In 2 recent studies of
melphalan and prednisone combined with standard-dose bor-
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tezomib given on a weekly basis for 6 to 9 cycles, the incidence of
grade 3 or 4 PN was reduced to 6% to 7%, whereas efficacy was
retained.97,98 Whether these favorable results may be obtained in
transplantation-eligible patients who usually receive a shorter
induction therapy is an issue not yet addressed in clinical trials.
Notably, compared with single-agent bortezomib short-term use of
combined bortezomib and thalidomide was not associated with a
major increase in the frequency of any grade and grade 3 or
4 PN.53,61,64,66 Besides symptomatic therapy, the optimal manage-
ment of bortezomib-induced PN requires its early recognition and
dose reduction or discontinuation of the drug using a validated
algorithm; an alternative option may be to prolong the dosing
schedule. Provided these procedures are promptly adopted, approxi-
mately 70% of patients have partial or complete reversibility of
their neurologic symptoms. The issue of the management of
treatment-emergent PN in MM has been recently addressed.99
Severe thrombocytopenia occurs in approximately 5% or less of
patients in the frontline setting. An additional adverse effect
commonly seen with bortezomib-based regimens is reactivation of
varicella zoster virus,100 a complication that can be virtually
abrogated with acyclovir prophylaxis.101
Role of novel agents as consolidation and
maintenance therapies after autologous
transplantation(s)
Consolidation treatment is generally short-term and aims to
improve responses after ASCT. Upgraded rates of CR and
CR-nCR, in the range between 10% and 30%, have been recently
reported with post-ASCT use of bortezomib or lenalidomide as
single agents102,103 or with VTD.104 In several of these studies,
consolidation therapy with VTD yielded molecular remissions in
up to 60% of patients.38,105
Maintenance treatment is given for a prolonged time period
with the goal of extending the duration of response, PFS, and OS,
while maintaining a good quality of life.106 Several randomized
studies showed a PFS benefit with thalidomide as single agent or
combined with prednisone as maintenance therapy after
ASCT.46,47,80,81,107,108 In 2 of these studies, OS was extended in the
thalidomide arm,80,107 a gain lost when thalidomide was also given
as part of induction therapy before ASCT.46,47,81 Concerns exist
about the use of thalidomide maintenance after ASCT, including
the possible emergence of tumor-resistant clones in patients with
prolonged exposure to this agents and its lack of efficacy in patients
with adverse cytogenetic abnormalities.109 However, the major
caveat that precludes a widespread use of thalidomide maintenance
is the toxicity related to long-term administration of this agent,
primarily PN. In several studies, thalidomide-induced PN led to
discontinuation rates in the 60% range46,81 and impairment in
patients’ quality of life.108 Lenalidomide is an attractive alternative
to thalidomide because of the lack of neurologic toxicity. Two
independent randomized trials have recently shown a significantly
longer PFS110,111 for patients randomized to lenalidomide mainte-
nance (5-15 mg/day) compared with the placebo group after a
single or double ASCT.105,106 An increased incidence of second
primary malignancies, in the 7% range, has been recently reported.
Although a concerted effort is needed to better define the underly-
ing mechanisms and identify risk factors, the optimal role and
duration of lenalidomide maintenance therapy need to be tested in
future clinical trials.
Conclusions
In conclusion, incorporation of IMiDs and/or bortezomib into
newer regimens given in preparation for ASCT has been exten-
sively explored using a wide range of different combinations.
Doublet therapies combining either an IMiD or bortezomib with
dexamethasone (eg, TD or Rd or VD) affected higher overall
response rates than traditional treatments,42,43,45,53 although the
lowest rate of high-quality responses was seen with TD. Compared
with doublets, such as TD and VD, triplet induction regimens, in
particular, bortezomib plus thalidomide and dexamethasone (VTD),
further increased the rate of CR and/or at least VGPR, both before
and after autotransplantation.61-63 In the context of triplet regimens
combining bortezomib with an IMiD, RVD is an attractive
alternative to VTD,70 although favorable results reported so far are
not backed by phase 3 clinical studies. Several newer induction
treatments, such as VD, VTD, PAD, and Rd, have been included as
a category 1 recommendation, which signifies a high-level of
evidence and uniform consensus among panel members, in the
United States National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology for Multiple Myeloma Version
1.2011.23
Enhanced high-quality responses affected by newer induction
regimens translated into even higher frequencies of CR or at least
VGPR after single or double ASCT. Although extended PFS was
reported in several of these studies,45,46,47,53,55,61 no OS benefit was
generally seen, a finding that reflects the lack of adequate power
and/or follow-up to detect survival differences. Furthermore,
proving an OS benefit at this time is probably difficult because of
the rapidly increasing availability of effective salvage therapies at
the time of relapse.
Based on these considerations and the close relationship
between maximal response to induction therapy and favorable
prognosis after ASCT, it is likely that many investigators in the
IMWG would recommend using one of the bortezomib-containing
triplet regimens as up-front induction therapy in a transplantation-
eligible MM patient. However, other IMWG investigators might
feel that until OS differences emerge, low-risk patients may have
the option of choosing either a doublet regimen with low morbidity,
such as Rd, or a bortezomib-based triplet, provided that they are
properly informed about the pros and cons, particularly the risk of
early PN with bortezomib. Besides once-weekly administration of
bortezomib, the introduction into the clinical practice of subcutane-
ous bortezomib that has recently shown a significantly lower risk of
PN compared with intravenous bortezomib in patients with relapsed/
refractory disease112 and carfilzomib, a second-generation irrevers-
ible proteasome inhibitor with significantly less neurotoxicity than
bortezomib, may solve some of these issues in the near future.
In the absence of randomized studies comparing different
induction regimens, it is difficult to recommend one induction
regimen over another. However, particular patient and disease
characteristics may guide the clinician to select the most appropri-
ate therapy. For instance, preliminary data suggest that bortezomib-
based regimens, such as VTD, VD, and PAD, can partially or
completely abrogate the poor prognosis related to t(4;14),55,61,78
although more mature data about del(17p) are needed. In patients
presenting with acute renal failure, both bortezomib- and
thalidomide-based regimens can be safely given, whereas lenalido-
mide requires appropriate dose reductions and frequent monitoring
of blood counts. In patients at high risk of thromboembolic
complications, a bortezomib-based regimen may be preferable. In
contrast, the presence of neuropathy at baseline might suggest
excluding bortezomib-based or thalidomide-based treatments in
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favor of a regimen, such as Rd. In the studies reported so far, the
dose of dexamethasone was variable. However, high-dose dexameth-
asone is needed in those patients in whom a prompt reduction in
tumor cell mass is required. Finally, it is worth remembering that in
many countries novel-agent-based induction therapies for younger,
transplantation-eligible patients are not approved as yet. In these
cases, the choice of induction regimen should be based on drug
availability; furthermore, referral of patients to a specialized
myeloma center with access to studies of novel agents is
recommended.
The usual choice of giving 3 to 6 cycles of induction therapy to
maximize the depth of response before early ASCT represents a
reasonable balance between maximum benefit and minimum
toxicity. However, an alternative choice that can be discussed with
the patient, particularly if response to therapy is favorable and
he/she is unwilling to proceed to early ASCT, is to continue
induction for as long as maximal tumor reduction is achieved and
then to maintain response until relapse or progression, at which
time salvage ASCT can be performed. In this scenario, especially in
patients treated with lenalidomide-based regimens, peripheral
blood stem cells should be collected early, after 4 to 6 cycles of
induction therapy. The best timing of ASCT in the novel agent era
represents an area of active debate and major interest. Unless final
results of ongoing clinical trials comparing early versus late ASCT
plus novel agents will be available, ASCT up-front should continue
to be considered the preferred approach for a patient who is eligible
to tolerate HDT. More recently, the treatment paradigm for
transplantation-eligible MM patients has continued to evolve with
the introduction of the novel agents as consolidation and mainte-
nance therapies. Mature results demonstrating the role, if any, of
consolidation therapy in improving clinical outcomes and the
impact of maintenance therapy on OS are needed before these
strategies are widely adopted. In the meantime, the choice of using
consolidation and/or maintenance therapy outside clinical trials is
at the patient’s and physician’s discretion. If post-ASCT therapy
with lenalidomide is planned, the IMWG recommends that the
benefits of extended disease control versus potential risks of second
malignancies with continued lenalidomide therapy be discussed
with each patient. For many other important and still unaddressed
questions, prospective randomized phase 3 studies are currently
planned or underway.
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